Grabba Technologies Pty Ltd

Australia|Electronic Equipment & Instruments

Business Highlights

Grabba Technologies Pty Ltd

'Grabba' is an advanced manufacturer of proprietary biometric devices (identity authentication products) and complex electronics. Since being acquired by its current owners in 2017, Grabba has strengthened its market position in two key markets:

North America: US Federal market with a focus on Customs and Border Protection (Department of Homeland Security); policing; and public safety.
Gulf States: Grabba is one of a select few biometric hardware manufacturers that supplies into the GCC market for commercial transactions. There are seven Gulf States that have developed national biometric databases and require personal identity checks for a growing range of commercial transactions, e.g., purchasing a SIM card, receiving courier deliveries, and banking (Know Your Customer (KYC) and Anti Money Laundering (AML)).

Grabba’s handheld devices are used to capture an individual’s biometric data, such as fingerprints, face and iris. To date over 20,000 devices have been sold globally.

The business has two divisions Grabba Technologies Pty Ltd (Grabba) and CrystalAid Manufacture Pty Ltd (CrystalAid). Both companies operate from a single modern manufacturing facility in Brisbane, Australia. All manufacturing phases (R&D, design, logistics, production, distribution, sales, and marketing) are controlled by the group with low supply chain risks. The micro-electronics and software (SDK) are developed and produced in house, which provides a level of security and resilience. Advanced production processes allow for rapid customisation of products to satisfy client specific needs. Enabling product customisation without margin erosion is a key differentiator in the market.

As an Australian manufacturer of biometric products, Grabba is perceived favourably by its growing cadre of high-profile repeat customers. Trusted relationships with the biometric data owners and national authorities are the true value of the company and creates a high barrier to entry for competitors. The level of trust that Grabba has established with customers and authorities is highly valuable and difficult to replicate. These relationships also provide a growth opportunity into the wider global market.

CrystalAid manufactures complex electronics (PCBs). Purchased in 2019, the facility was originally the manufacturing arm of Cochlear implants and now manufactures the core microelectronics for the Grabba product. As one the few AS9100D certified companies with core capabilities in electronics manufacturing, it also produces non-proprietary products for the defence, aerospace, medical, mining, and other commercial sectors.

Problem and Solution

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.

Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.

Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.

Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.

Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urna accumsan lacinia. Sed sed enim volutpat, malesuada metus ut, lobortis lectus. Sed vulputate fringilla justo, sed condimentum tellus fermentum sit amet. Pellentesque tempus elit id dapibus ornare. Phasellus accumsan suscipit elit. Donec eget libero eget neque cursus bibendum. Praesent lacinia felis et aliquam condimentum. Proin vestibulum posuere tortor at finibus. Etiam posuere neque eu elit sollicitudin sollicitudin. Sed viverra ante eros, et maximus tortor viverra et.

Quisque a nunc maximus, eleifend est eget, mattis mauris. Aliquam non eleif

Open an account to get
access to more details

Market Opportunity

Cras eleifend purus vitae mattis imperdiet.

Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.

Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.

Fusce scelerisque massa sit amet turpis rutrum semper.

Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.

Open an account to get
access to more details

Competitive Advantage

Open an account to get
access to more details

Highlights & Milestones

Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.

Duis vitae mi neque.

Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.

Proin neque lacus, semper vel ex at, eleifend rhoncus est.

Cras non nisi urna. Sed feugiat dign

Open an account to get
access to more details

See more exiting opportunities on CapitalHQ

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

New Zealand NZD

Biotechnology Series B+

ProxyTwin

ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...

Australia AUD

Artificial Intelligence Seed Round

HorizonTwo Capital Partners

HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.

Australia AUD

Advanced Manufacturing Private Placement

The Insides Company

First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.

New Zealand AUD

Medical Devices Series A

DCARB

We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.

Australia CAD

Green Hydrogen Series B+